Is Fervent Synerg. overvalued or undervalued?

As of 4 July 2025, the valuation grade for Fervent Synerg. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 32.43, an EV to EBITDA of 32.07, and a PEG ratio of 0.28, which indicates strong growth potential relative to its price.
In comparison to peers, Fervent Synerg. has a lower PE ratio than Sun Pharma. Inds. at 35.2 and Divi's Lab. at 83.9, both of which are classified as expensive. Notably, its PEG ratio of 0.28 suggests it may offer better growth prospects than some of its more expensive counterparts. While Fervent Synerg. has underperformed the Sensex over the past month and year, it has shown a positive return of 16.43% over the last year, indicating potential for recovery.